Braveheart Bio (NASDAQ:BRVE) Now Covered by Analysts at Cantor Fitzgerald

Analysts at Cantor Fitzgerald started coverage on shares of Braveheart Bio (NASDAQ:BRVE) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $40.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 45.77% from the stock’s previous close.

Several other research analysts also recently commented on BRVE. Jefferies Financial Group initiated coverage on Braveheart Bio in a research note on Monday. They issued a “buy” rating and a $48.00 target price for the company. TD Cowen assumed coverage on Braveheart Bio in a research report on Monday. They set a “buy” rating on the stock. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Finally, The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research report on Monday. They issued a “buy” rating and a $48.00 price objective for the company. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $45.25.

Braveheart Bio Stock Performance

Shares of NASDAQ BRVE opened at $27.44 on Monday. Braveheart Bio has a fifty-two week low of $24.61 and a fifty-two week high of $32.00.

Insider Buying and Selling at Braveheart Bio

In related news, major shareholder Growth Opportunities F. Forbion acquired 1,680,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $18.00 per share, with a total value of $30,240,000.00. Following the acquisition, the insider owned 10,185,478 shares of the company’s stock, valued at approximately $183,338,604. The trade was a 19.75% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Orbimed Advisors Llc bought 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the purchase, the director owned 11,901,826 shares of the company’s stock, valued at $214,232,868. The trade was a 19.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 over the last quarter.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.